FDA Cites Sterility Risk in Spectra Saline Flush Recall

FDA has classified a Class I recall — the agency’s most serious category, reserved for products with a reasonable probability of causing serious injury or death — for Spectra Medical Devices’ 10 mL Sodium Chloride Injection 0.9% USP flush ampules. The product itself is unremarkable: a saline flush, used constantly across hospitals and infusion centers to clear IV tubing and indwelling lines before and after use. What is not unremarkable is the paper trail behind the recall, which runs through an unannounced FDA inspection in Korea, a CGMP warning letter, and a voluntary recall the manufacturer had already committed to months earlier.

A recall that starts with an inspection finding, not a patient complaint

This recall did not start with a cluster of adverse events. It started with an FDA inspector walking Huons’ Jecheon facility from 12 to 21 November 2025 and finding what the agency's subsequent warning letter describes as insufficient sterility assurance on certain production lines. That is the pattern behind a large share of drug and device recalls that never make headlines until the recall notice itself appears: a CGMP finding during a routine or for-cause inspection, followed months later by a warning letter, and only then a public recall notice once the firm and FDA agree on scope. Huons received its warning letter, No. 724650, on 15 June 2026, covering CGMP violations for finished pharmaceuticals at the same facility. Roughly three months before that letter issued, on 25 March 2026, Huons had already committed to a facility-wide voluntary recall — meaning the firm moved before the warning letter was finalized, a sequence worth noting for any manufacturer weighing when to act on an inspection finding rather than wait for FDA's written conclusions.

A drug product, tracked on a device-adjacent page

One detail is worth flagging for anyone pulling this recall up directly: Sodium Chloride Injection 0.9% USP is an approved drug product, not a device, and Huons’ warning letter is a CDER (drug) enforcement action. FDA nonetheless lists this recall on its medical-device recalls and early-alerts page — almost certainly because Spectra’s ampules ship as components inside IV and procedural convenience kits that CDRH otherwise regulates, and several kit manufacturers have separately issued their own corrections referencing these same ampules. The practical result for a hospital or GPO tracking this recall is the same either way: pull affected lots regardless of which FDA center's letterhead the notice happens to carry.

Scope and what is still unconfirmed

Affected lots span nearly three years of production, from 1 April 2023 through 5 March 2026 — a wide window that reflects how far back a sterility-assurance finding can reach once a firm and FDA agree the underlying manufacturing controls, not a single batch, were the problem. FDA and Spectra have not published a specific unit or lot count in the material Regulatory News could review, and Spectra's most recent public injury tally — no reports of serious injury or death — is dated 6 July 2026, weeks before the Class I classification. Whether that figure has since changed is not publicly confirmed.

Frequently asked questions

What did FDA classify as a Class I recall?

Spectra Medical Devices' 10 mL Sodium Chloride Injection 0.9% USP flush ampules, used to flush IV tubing and indwelling intravascular access devices such as central lines, PICC lines and implanted ports.

Why was it recalled?

Sterility-assurance deficiencies on certain production lines at the manufacturing site, risking exposure to microorganisms, endotoxins or foreign matter that can trigger systemic inflammatory responses, infections, micro-clots, organ failure, or — for use near the spine — abscess, meningitis or paralysis.

Where are the ampules made, and what led to this?

Huons Co., Ltd.'s facility in Jecheon, South Korea. An unannounced FDA inspection from 12–21 November 2025 found insufficient sterility assurance, escalated to a CDER warning letter on 15 June 2026. Huons had already committed to a facility-wide voluntary recall on 25 March 2026; affected lots span 1 April 2023 to 5 March 2026.

Have any injuries been reported?

As of 6 July 2026, before the Class I classification, Spectra said it had not received reports of serious injury or death. Whether that has since changed is not publicly confirmed.